secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0000805928-25-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q4 2024 revenue up 15.1% to $49.4M; reports first quarterly net income of $0.4M
--------------------------------------------------------------------------------

- Q4 revenue $49.4M (+15.1% YoY); gross margin 76.1% vs 74.6%.
- Q4 net income $0.4M ($0.01 EPS) vs net loss $3.9M prior year; adjusted net income $3.5M ($0.07 EPS).
- Full-year 2024 revenue $187.3M (+17.8% YoY); adjusted EBITDA $19.8M vs -$1.1M in 2023.
- FDA accepted BLA for Avance Nerve Graft; PDUFA goal date Sept 5, 2025; anticipates approval.
- 2025 guidance: revenue growth 15-17%, gross margin 73-75%, expects positive net cash flow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592825000010/0000805928-25-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592825000010/axgn-20250225.htm
  HTML page:      https://secwatch.observer/filing/0000805928-25-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer